Long-term Survival Following CAR T Cell Therapy to Treat Neuroblastoma
February 19, 2025
February 19, 2025
HOUSTON, Texas, Feb. 19 -- The Baylor College of Medicine issued the following news:
* * *
Long-term survival following CAR T cell therapy to treat neuroblastoma
Houston, TX - Feb 17, 2025
An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent the longest reported remission to date in a patient treated with chimeric antigen receptor (CAR) T cell therapy. The findings, publi . . .
* * *
Long-term survival following CAR T cell therapy to treat neuroblastoma
Houston, TX - Feb 17, 2025
An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent the longest reported remission to date in a patient treated with chimeric antigen receptor (CAR) T cell therapy. The findings, publi . . .